South Dakota Investment Council Sells 14,956 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

South Dakota Investment Council trimmed its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 59.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,153 shares of the biotechnology company’s stock after selling 14,956 shares during the period. South Dakota Investment Council’s holdings in Sarepta Therapeutics were worth $1,235,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SRPT. Manchester Capital Management LLC grew its position in shares of Sarepta Therapeutics by 86.6% in the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after buying an additional 110 shares during the period. MassMutual Private Wealth & Trust FSB lifted its position in Sarepta Therapeutics by 169.6% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. boosted its stake in Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 232 shares in the last quarter. Huntington National Bank grew its holdings in Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 175 shares during the period. Finally, Newbridge Financial Services Group Inc. bought a new position in shares of Sarepta Therapeutics during the fourth quarter valued at approximately $36,000. Institutional investors own 86.68% of the company’s stock.

Insider Buying and Selling

In other news, Director Kathryn Jean Boor sold 1,636 shares of the firm’s stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This trade represents a 21.77 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on SRPT. StockNews.com cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Needham & Company LLC reissued a “buy” rating and issued a $202.00 target price on shares of Sarepta Therapeutics in a report on Monday, January 27th. Evercore ISI reduced their price target on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a report on Thursday, November 7th. Robert W. Baird dropped their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $152.00 to $167.00 in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $176.77.

Sarepta Therapeutics Trading Down 2.0 %

Sarepta Therapeutics stock opened at $106.28 on Monday. Sarepta Therapeutics, Inc. has a 52-week low of $101.15 and a 52-week high of $173.25. The company has a market cap of $10.15 billion, a P/E ratio of 85.02 and a beta of 0.75. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The business has a 50-day simple moving average of $117.54 and a two-hundred day simple moving average of $123.36.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.